Header links
Intranet
Donate now
image/svg+xml Map
Contact us

David Tabernero Caellas

David Tabernero Caellas

Institutions of which they are part

Senior researcher
Liver Diseases
Vall Hebron Institut de Recerca
David Tabernero Caellas

David Tabernero Caellas

David Tabernero Caellas

Institutions of which they are part

Senior researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

(Standard-D) Standardization of HDV-RNA quantification: a need that can no longer be ignored.

IP: -
Collaborators: David Tabernero Caellas
Funding agency: GILEAD SCIENCES SLU
Funding: 49961.71
Reference: GLD22/00080
Duration: 28/02/2023 - 27/02/2025

Malalties hepàtiques

IP: Joan Genescà Ferrer
Collaborators: Beatriz Minguez Rosique, Sergi Colomer Castell, Elena Vargas Accarino, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Maria Buti Ferret, Montserrat Gomez Perez, Judit Romero Vico, Josep Quer Sivila, Adriana Palom Agusti, Juan Manuel Pericàs Pulido, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Daniel Martinez Vazquez, Laura Puente Ramo, Isabel Campos Varela, María Bermúdez Ramos, Juan Ignacio Esteban Mur, Ester Palacio Gutierrez, Susana Anton Calvo, Monica Higuera Urbano, Meritxell Ventura Cots, Ares Aurora Villagrasa Vilella, Emma Bigas Alsina, Carolina Campos Martinez, Macarena Simon-Talero Horga, David Tabernero Caellas, Mònica Pons Delgado, Marcella Salzano
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00462
Duration: 01/01/2022 - 30/06/2025

Optimización del algoritmo diagnóstico para el cribado de infección por virus de la hepatitis D en la población atendida en el área de cobertura de la sanidad pública de la ciudad de Barcelona.

IP: Ariadna Rando Segura
Collaborators: Maria Buti Ferret, David Tabernero Caellas, Maria Francesca Cortese
Funding agency: GILEAD SCIENCES SLU
Funding: 27000
Reference: GILEAD/HEPATITIS/2022/RANDO
Duration: 22/02/2023 - 21/02/2025

Estudio de la quasiespecies del gen X en ARN circulante del virus de la hepatitis B (ARN-VHB): en búsqueda de nuevos factores pronósticos y dianas para terapia génica.

IP: -
Collaborators: Lluis Castells Fusté, Andrea Caballero Garralda, David Tabernero Caellas, Maria Francesca Cortese
Funding agency: Instituto de Salud Carlos III
Funding: 159720
Reference: PI18/01436
Duration: 01/01/2019 - 31/12/2022

Related news

Dr. Raul Herance

We develop a method to diagnose fatty liver in a quantitative and non-invasive way

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Pacient d'un assaig clínic a la consulta

VHIR exceeds 700 active clinical trials to achieve new therapies for patients

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Grup de Malalties Hepàtiques del VHIR

A clinical trial has led to approval of the first drug for advanced fatty liver disease

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

See more

Related professionals

Roser Navarro García

Roser Navarro García

Infectious Diseases
Read more
Mª Carmen López Arribas

Mª Carmen López Arribas

Research technician
Molecular Medical Imaging
Read more
Jesús Francisco Lopez Lozano

Jesús Francisco Lopez Lozano

Read more
Jorge Serra Pueyo

Jorge Serra Pueyo

Main researcher
Physiology and Pathophysiology of the Digestive Tract
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.